MED12L-associated chromatin changes in a pediatric leukemia linked to poor outcomes
Official title: Role of MED12L- Associated Chromatin Enhancers in Pediatric Acute Megakaryoblastic Leukemia
Funded at Arkansas Children's Hospital Res Inst · NIH-11386607 · Data updated 2026-11-12
This grant explores how specific gene-related changes drive a dangerous pediatric leukemia and aims to uncover new angles for better treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arkansas Children's Hospital Res Inst NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project start | July 11, 2017 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $411,236 |
| NIH project number | 5P20GM121293-10 |
| Project ID | NIH-11386607 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are children under 11 diagnosed with acute megakaryoblastic leukemia, especially those with ETO2-GLIS2 fusion.
✕Less likely to help
Patients without this specific leukemia subtype or without the targeted genetic alterations may not directly benefit from this research.
What this research studies
The project focuses on AMKL in young children with a high-risk ETO2-GLIS2 fusion and studies how MED proteins help shape chromatin to drive leukemia. Researchers will examine how these chromatin changes alter gene activity and contribute to the disease's aggressiveness. By mapping these mechanisms, the team hopes to identify potential targets for future therapies that could improve responses and survival for affected children.
Why it matters
Potential benefit: If successful, the work could point to new strategies to treat a high-risk pediatric leukemia and improve long-term outcomes for vulnerable patients.
How similar studies have gone: Previous work has linked chromatin regulation to leukemogenesis, with some success in identifying regulatory elements that could be therapeutic targets; this study builds on that foundation with a pediatric focus.
Where this research is happening
-
Arkansas Children's Hospital Res Inst
Little Rock, United States Active
Researchers
- Principal investigator: Roy Choudhury, Samrat — Arkansas Children's Hospital Res Inst
- Study coordinator: Roy Choudhury, Samrat
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.